Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.

Article  PubMed  Google Scholar 

Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Prz Gastroenterol. 2019;14(2):89–103.

CAS  PubMed  PubMed Central  Google Scholar 

Aliberti C, Fiorentini G, Muzzio PC, Pomerri F, Tilli M, Dallara S, Benea G. Trans-arterial chemoembolization of metastatic colorectal carcinoma to the liver adopting DC Bead®, drug-eluting bead loaded with irinotecan: results of a phase II clinical study. Anticancer Res. 2011;31(12):4581–7.

CAS  PubMed  Google Scholar 

Biller LH, Schrag D. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA. 2021;325(7):669–85.

Article  CAS  PubMed  Google Scholar 

Donadon M, Ribero D, Morris-Stiff G, Abdalla EK, Vauthey JN. New paradigm in the management of liver-only metastases from colorectal cancer. Gastrointest Cancer Res. 2007;1(1):20–7.

PubMed  PubMed Central  Google Scholar 

Li CC, Chang TK, Chen YC, Tsai HL, Huang CW, Su WC, Ma CJ, Yin TC, Chen PJ, Wang JY. Clinical outcomes of patients with peritoneal metastasis-only colorectal cancer treated with first-line bevacizumab and FOLFIRI through irinotecan dose escalation according to UGT1A1 polymorphism: compared to liver metastasis-only, and lung metastasis-only. Cancer Manag Res. 2022;14:1541–9.

Article  PubMed  PubMed Central  Google Scholar 

Tsai HL, Huang CW, Lin YW, Wang JH, Wu CC, Sung YC, Chen TL, Wang HM, Tang HC, Chen JB, et al. Determination of the UGT1A1 polymorphism as guidance for irinotecan dose escalation in metastatic colorectal cancer treated with first-line bevacizumab and FOLFIRI (PURE FIST). Eur J Cancer (Oxford, England : 1990). 2020;138:19–29.

Article  CAS  Google Scholar 

Martin RC 2nd, Scoggins CR, Schreeder M, Rilling WS, Laing CJ, Tatum CM, Kelly LR, Garcia-Monaco RD, Sharma VR, Crocenzi TS, et al. Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis. Cancer. 2015;121(20):3649–58.

Article  CAS  PubMed  Google Scholar 

Peeters M, Price T. Biologic therapies in the metastatic colorectal cancer treatment continuum–applying current evidence to clinical practice. Cancer Treat Rev. 2012;38(5):397–406.

Article  PubMed  Google Scholar 

Martin RC, Joshi J, Robbins K, Tomalty D, Bosnjakovik P, Derner M, Padr R, Rocek M, Scupchenko A, Tatum C. Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study. Ann Surg Oncol. 2011;18(1):192–8.

Article  PubMed  Google Scholar 

Richardson AJ, Laurence JM, Lam VW. Transarterial chemoembolization with irinotecan beads in the treatment of colorectal liver metastases: systematic review. J Vasc Interv Radiol. 2013;24(8):1209–17.

Article  PubMed  Google Scholar 

Martin RC, Robbins K, Tomalty D, O’Hara R, Bosnjakovic P, Padr R, Rocek M, Slauf F, Scupchenko A, Tatum C. Transarterial chemoembolisation (TACE) using irinotecan-loaded beads for the treatment of unresectable metastases to the liver in patients with colorectal cancer: an interim report. World J Surg Oncol. 2009;7:80.

Article  PubMed  PubMed Central  Google Scholar 

Nam HC, Jang B, Song MJ. Transarterial chemoembolization with drug-eluting beads in hepatocellular carcinoma. World J Gastroenterol. 2016;22(40):8853–61.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fiorentini G, Sarti D, Nani R, Aliberti C, Fiorentini C, Guadagni S. Updates of colorectal cancer liver metastases therapy: review on DEBIRI. Hepat Oncol. 2020;7(1):Hep16.

Article  PubMed  PubMed Central  Google Scholar 

Mokkarala M, Noda C, Malone C, Ramaswamy R, Akinwande O. Comparison of response and outcomes of drug-eluting bead chemoembolization (DEB-TACE) versus radioembolization (TARE) for patients with colorectal cancer liver metastases. Anticancer Res. 2019;39(6):3071–7.

Article  CAS  PubMed  Google Scholar 

Aliberti C, Tilli M, Benea G, Fiorentini G. Trans-arterial chemoembolization (TACE) of liver metastases from colorectal cancer using irinotecan-eluting beads: preliminary results. Anticancer Res. 2006;26(5b):3793–5.

CAS  PubMed  Google Scholar 

Vogl TJ, Marko C, Langenbach MC, Naguib NNN, Filmann N, Hammerstingl R, Gruber-Rouh T. Transarterial chemoembolization of colorectal cancer liver metastasis: improved tumor response by DSM-TACE versus conventional TACE, a prospective, randomized, single-center trial. Eur Radiol. 2021;31(4):2242–51.

Article  PubMed  Google Scholar 

National Comprehensive Cancer Network(NCCN) Guidelines Version 1.2021 Colon Cancer [https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1428.

Tsai HL, Chen YC, Yin TC, Su WC, Chen PJ, Chang TK, Li CC, Huang CW, Wang JY: Comparison of UGT1A1 polymorphism as guidance of irinotecan dose escalation in RAS wild type metastatic colorectal cancer patients treated with cetuximab or bevacizumab plus FOLFIRI as the first-line therapy. Oncology research 2022.

Chen YC, Chuang CH, Miao ZF, Yip KL, Liu CJ, Li LH, Wu DC, Cheng TL, Lin CY, Wang JY. Gut microbiota composition in chemotherapy and targeted therapy of patients with metastatic colorectal cancer. Front Oncol. 2022;12:955313.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen HH, Ke TW, Huang CW, Jiang JK, Chen CC, Hsieh YY, Teng HW, Lin BW, Liang YH, Su YL, et al. Taiwan Society of Colon and Rectal Surgeons Consensus on mCRC treatment. Front Oncol. 2021;11:764912.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schwartz LH, Litière S, de Vries E, Ford R, Gwyther S, Mandrekar S, Shankar L, Bogaerts J, Chen A, Dancey J, et al. RECIST 1.1-Update and clarification: from the RECIST committee. Eur J Cancer. 2016;62:132–7.

Article  PubMed  PubMed Central  Google Scholar 

Common Terminology Criteria for Adverse Events (CTCAE) v4.0 [https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm#ctc_40.

Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, Lang H, Frilling A, Stoehlmacher J, Weitz J, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol. 2010;11(1):38–47.

Article  CAS  PubMed  Google Scholar 

Ji JH, Park SH, Lee J, Kim TW, Hong YS, Kim KP, Kim SY, Baek JY, Kang HJ, Shin SJ, et al. Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis. Cancer Chemother Pharmacol. 2013;72(1):223–30.

Article  CAS  PubMed  Google Scholar 

Huppert P, Wenzel T, Wietholtz H. Transcatheter arterial chemoembolization (TACE) of colorectal cancer liver metastases by irinotecan-eluting microspheres in a salvage patient population. Cardiovasc Intervent Radiol. 2014;37(1):154–64.

Article  PubMed  Google Scholar 

Boccia RV, Cosgriff TM, Headley DL, Badarinath S, Dakhil SR. A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer. Clin Colorectal Cancer. 2010;9(2):102–7.

Article  CAS  PubMed  Google Scholar 

McCleary NJ, Harmsen WS, Haakenstad E, Cleary JM, Meyerhardt JA, Zalcberg J, Adams R, Grothey A, Sobrero AF, Van Cutsem E, et al. Metastatic colorectal cancer outcomes by age among ARCAD first- and second-line clinical trials. JNCI Cancer Spectr. 2022;6(2):pkac014.

Article  PubMed  PubMed Central  Google Scholar 

Claramunt García R, Muñoz Cid CL, Sánchez Ruiz A, Marín Pozo JF. Bevacizumab and aflibercept in second-line metastatic colorectal cancer: 12 years of experience. Eur J Clin Pharmacol. 2022;78(2):287–91.

Article  PubMed  Google Scholar 

Vogl TJ, Lahrsow M. The role of conventional TACE (cTACE) and DEBIRI-TACE in colorectal cancer liver metastases. Cancers. 2022;14(6):1503.

Article  PubMed  PubMed Central  Google Scholar 

Vogl TJ, Lahrsow M, Albrecht MH, Hammerstingl R, Thompson ZM, Gruber-Rouh T. Survival of patients with non-resectable, chemotherapy-resistant colorectal cancer liver metastases undergoing conventional lipiodol-based transarterial chemoembolization (cTACE) palliatively versus neoadjuvantly prior to percutaneous thermal ablation. Eur J Radiol. 2018;102:138–45.

Article  PubMed  Google Scholar 

Fiorentini G, Aliberti C, Tilli M, Mulazzani L, Graziano F, Giordani P, Mambrini A, Montagnani F, Alessandroni P, Catalano V, et al. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res. 2012;32(4):1387–95.

CAS  PubMed  Google Scholar 

Stutz M, Mamo A, Valenti D, Hausvater A, Cabrera T, Metrakos P, Chaudhury P, Steacy G, Garoufalis E, Kavan P. Real-life report on chemoembolization using DEBIRI for liver metastases from colorectal cancer. Gastroenterol Res Pract. 2015;2015:715102.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Akinwande O, Dendy M, Ludwig JM, Kim HS. Hepatic intra-arterial injection of irinotecan drug eluting beads (DEBIRI) for patients with unresectable colorectal liver metastases: a systematic review. Surg Oncol. 2017;26(3):268–75.

Article  PubMed  Google Scholar 

Nappi A, Berretta M, Romano C, Tafuto S, Cassata A, Casaretti R, Silvestro L, Divitiis C, Alessandrini L, Fiorica F, et al. Metastatic colorectal cancer: role of target therapies and future perspectives. Curr Cancer Drug Targets. 2018;18(5):421–9.

Article  CAS  PubMed  Google Scholar 

Zhao G, Liu S, Zhang Y, Zhao T, Wang R, Bian J, Wu J, Zhou J. Irinotecan eluting beads-transarterial chemoembolization using Callispheres® microspheres is an effective and safe approach in treating unresectable colorectal cancer liver metastases. Ir J Med Sci. 2022;191(3):1139–45.

Article  CAS  PubMed  Google Scholar 

Jones RP, Malik HZ, Fenwick SW, Terlizzo M, O’Grady E, Stremitzer S, Gruenberger T, Rees M, Plant G, Figueras J, et al. PARAGON II - A single arm multicentre phase II study of neoadjuvant therapy using irinotecan bead in patients with resectable liver metastases from colorectal cancer. Eur J Surg Oncol. 2016;42(12):1866–72.